Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation

[1]  Patrick J. Paddison,et al.  A kinase-deficient NTRK2 splice variant predominates in glioma and amplifies several oncogenic signaling pathways , 2020, Nature Communications.

[2]  Liangsong Zhu,et al.  ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma , 2020, Cell Death & Disease.

[3]  F. Santini,et al.  TRK Inhibitors in Non-Small Cell Lung Cancer , 2020, Current Treatment Options in Oncology.

[4]  R. Mehra,et al.  New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1) , 2020, Current Oncology Reports.

[5]  C. Arteaga,et al.  Overcoming Endocrine Resistance in Breast Cancer. , 2020, Cancer cell.

[6]  B. Taylor,et al.  Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers , 2019, Nature.

[7]  B. Taylor,et al.  EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. , 2018, Cancer discovery.

[8]  J. Krauss,et al.  Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  A. Drilon,et al.  NTRK fusion-positive cancers and TRK inhibitor therapy , 2018, Nature Reviews Clinical Oncology.

[10]  J. Krauss,et al.  Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J. Roth,et al.  Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC , 2018, Clinical Cancer Research.

[12]  A. Drilon,et al.  Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. , 2018, Cancer discovery.

[13]  A. Drilon,et al.  Activity of larotrectinib in patients with TRK fusion GI malignancies. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Jessica L. Davis,et al.  Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. , 2018, The Lancet. Oncology.

[15]  Funda Meric-Bernstam,et al.  Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.

[16]  Ying Cheng,et al.  Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer , 2018 .

[17]  M. Cabanillas.  Faculty of 1000 evaluation for Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). , 2018 .

[18]  B. Taylor,et al.  HER kinase inhibition in patients with HER2- and HER3-mutant cancers , 2018, Nature.

[19]  Lu Wang,et al.  Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. , 2017, Cancer research.

[20]  B. Taylor,et al.  A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. , 2017, Cancer discovery.

[21]  A. Drilon,et al.  Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance , 2017, Nature Reviews Clinical Oncology.

[22]  Rafal Dziadziuszko,et al.  Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[23]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[24]  A. Drilon,et al.  Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). , 2017, Cancer discovery.

[25]  A. Bardelli,et al.  MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. , 2016, Cancer discovery.

[26]  Jeffrey W. Clark,et al.  Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  Grant W. Brown,et al.  HELB Is a Feedback Inhibitor of DNA End Resection. , 2016, Molecular cell.

[28]  Mari Mino-Kenudson,et al.  Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. , 2016, Cancer discovery.

[29]  Gang Li,et al.  Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. , 2015, Cancer discovery.

[30]  N. Socci,et al.  Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity , 2015, Nature Biotechnology.

[31]  S. Cook,et al.  MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road , 2015, Nature Reviews Cancer.

[32]  M. Nowak,et al.  Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers , 2015, Nature Communications.

[33]  F. Nicolantonio,et al.  Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.

[34]  John C. Hunter,et al.  Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations , 2015, Molecular Cancer Research.

[35]  Beatriz Bellosillo,et al.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.

[36]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[37]  J. Utikal,et al.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.

[38]  Richard F. Kefford,et al.  Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients , 2014, Clinical Cancer Research.

[39]  Andrea Bertotti,et al.  Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. , 2013, Cancer discovery.

[40]  K. Flaherty,et al.  Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[41]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[42]  Jie Qi,et al.  Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. , 2011, Cancer research.

[43]  Luca Toschi,et al.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.

[44]  N. Socci,et al.  Accelerating Discovery of Functional Mutant Alleles in Cancer. , 2018, Cancer discovery.

[45]  R. Doebele,et al.  TRKing down an old oncogene in a new era of targeted therapy. , 2015, Cancer discovery.

[46]  C. Hancock.  The long and winding road , 2005, Nature Reviews Drug Discovery.

[47]  M. Barbacid,et al.  A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences , 1986, Nature.